Introduction/Background The primary objective of the study was to evaluate the overall survival of women with advanced stage (Stage IIIA–IV) high-grade serous ovarian cancer in Republic of North Macedonia.

Methodology The study was a cross-sectional medical record review of patients diagnosed with advanced stage HGSC. Patients were deemed eligible for inclusion if they were diagnosed with an advanced stage (Stage IIIA–IV) HGSC of the ovary, fallopian tube or peritoneum between 2009 and 2015. The data was analyzed in a descriptive fashion and summary statistics were provided, as appropriate. Survival was calculated using the Kaplan-Meier method.

Results A total of 81 eligible patients were identified and included in the study. The average overall survival in the studied cohort was 46.59 months (95% CI 39.11–54.06). Patients that were optimally debulked and patients that had a platinum free interval larger than 12 months had significantly longer survival in the current series (p<0.001).

Conclusion The average overall survival of advanced stage HGSC patients in the studied series was 46.59 months (95% CI 39.11–54.06). Patients aged 65 years or younger had a tendency to live approximately 10 months longer than patients older than 65 years, but this difference was not statistically significant. There was no difference in HGSC survival in the groups of patients with grade 2 and grade 3 disease. However, optimal surgical debulking and platinum sensitivity were associated with significantly better overall survival.

Disclosure Nothing to disclose.